RPL22 and infection: For the purpose of tailoring therapy, we introduced three groups of patients to clinicians: first, CAM-R infected subjects (Tagged for 23S rRNA and rpl22 related point mutations) for drug replacement or alternative treatment regime in use; second, PM patients in CAM-S group (that may suffer from long-term PPIs and side effects), and CAM-R groups; finally, EM patients that the risk of infection recurrence by standard PPIs dose scheduling consider to be very high.